Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims is from April 29, 2025, to June 23, 2025 [2]. - The complaint claims that Hims engaged in deceptive promotion and selling of knockoff versions of Wegovy, risking patient safety [2]. - There is a substantial risk that the collaboration with Novo Nordisk could be terminated due to these practices [2]. - The positive statements made by the defendants regarding the company's business and operations were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased HIMS shares during the class period are encouraged to register for potential lead plaintiff appointment [1][3]. - The deadline for shareholders to register is August 25, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing allegations of providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant stock price decline after the FDA placed a clinical hold on the study due to serious adverse events, including a participant's death [1]. Summary by Relevant Sections Allegations - The complaint states that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol [1]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing shares at inflated prices [1]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a serious adverse event, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [1]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action lawsuit, with a deadline of August 11, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions [3].